Skip to content

Webinar: The potential of iPSC-derived endothelial cells for efficacy and safety screenings

By Jessica Koepke

Human iPSC-derived endothelial cells enable detailed understanding of drug effects on vascular function and vessel formation

As endothelial cells are involved in many biological processes, they hold great potential for in vitro drug screening. However, there is a lack of scalable assays and a need for large-scale batches to bring higher reproducibility and accuracy during early and preclinical drug discovery.
To meet these requirements, relevant in vitro models of the vasculature, amenable for high-throughput are needed. Human induced pluripotent stem cells (iPSC), differentiated into endothelial cells and manufactured at large scale, are a powerful tool to fulfill these needs.

Human iPSC-derived endothelial cells enable detailed understanding of drug effects on vascular function and angiogenesis that is key to identify and validate targets for treatments for a variety of diseases and evaluate drug-induced compound effects for safety screenings.

In this webinar, we present the potential of Ncardia's iPSC-derived endothelial cell models. We have developed a controlled process for large-scale manufacturing of iPSC-derived endothelial cells and scalable assays for drug efficacy and safety screenings, with the aim of bringing better medicines to patients faster

Webinar
4727277c37bf92db-400x0-0-files-Events-WEBINAR-Poster_07Replay-Webinar-replay-The-potential-of-iPSC-derived-endothelial-cells-for-efficacy-and-safety-s

Objectives:
In this webinar you will:

  1. Gain insights into the advantages of iPSC-based models versus primary cell models

  2. Learn how human iPSC-derived endothelial cells enable detailed understanding of drug effects on vascular function and vessel formation

  3. Discover future potential applications of iPSC-derived endothelial cells

Fill in the form below to watch the replay